Life Biosciences

We are pleased to share our CSO, Dr. Sharon Rosenzweig-Lipson, recently interviewed with Arkadi Mazin at Lifespan.io News Outlet! In this article you can learn more about: 💪 Life Bio’s focus on #healthspan 🧬 Partial #EpigeneticReprogramming with OSK 👁️ Our progress towards the clinic to treat #OpticNeuropathies Read more here: https://bit.ly/40nBleI

We are honored to have had our work in partial #EpigeneticReprogramming recognized by Ophthalmology Times in a roundup piece highlighting key findings from this year’s #AAO meeting. Read more about ER-100 and our efforts to restore #VisualFunction in patients with optic neuropathies here: https://bit.ly/3Ykoas5

Today, we announced data shared at #AAO highlighting the ongoing progress of our partial #EpigeneticReprogramming platform to restore visual function in a model of #NAION. Results replicate and expand our knowledge about the potential of ER-100, and we look forward to advancing this program for patients affected by age-related optic neuropathies.    Read more here: https://lnkd.in/gssWx5-e

Our CSO, Dr. Sharon Rosenzweig-Lipson, will present at the upcoming American Academy of Ophthalmology (#AAO) Meeting in Chicago from October 18-21. If you are registered, join us in person or virtually to hear updates on our partial #EpigeneticReprogramming platform to treat #OpticNeuropathies.

We are excited to share that Life Biosciences has been named a 2024 #INNOFIRE Award honoree by BostInno! This competitive award celebrates our efforts in advancing #CellularRejuvenation therapies to reverse and prevent diseases of aging, positioning us among the leading innovators in Boston’s thriving biotech scene. Thank you to our incredible team and supporters for helping us reach this milestone. Learn more: https://bit.ly/4f4MR2u

“There’s a whole host of hallmarks of aging—it’s not just ‘wear and tear.’” Check out this Genetic Engineering & Biotechnology News article on reversing aging’s clock featuring our CSO, Dr. Sharon Rosenzweig-Lipson. She highlights Life Biosciences’ #EpigeneticReprogramming platform and its potential to modify gene expression and shares insights on the groundbreaking research we are conducting to target cellular mechanisms of aging. Read more in the article: https://bit.ly/47VJZCO

We are excited to share that our CEO, Jerry McLaughlin, will be speaking at Fierce Life Sciences Events Fierce Biotech Summit in Boston on Monday, September 30 at 4pm ET. Join us as he shares his insights on fostering strategic collaborations to accelerate #DrugDevelopment and building partnerships that enable us to advance groundbreaking therapies efficiently and effectively. View the agenda and register here: https://lnkd.in/gZiJ8nHE

Our Senior Vice President for CMC Operations, Michel Wathier, Ph.D. will be presenting today at BioProcess International in Boston. Check out our poster for more on our approach to treating #AgeRelatedDisease. For more details on the event visit: https://bit.ly/2VLt2KM

In case you missed it, our CEO, Jerry McLaughlin, attended the 11th Aging Research & Drug Discovery Meeting 2024 in Copenhagen! He shared an update on our #EpigeneticReprogramming platform and participated in a panel for biotechs specializing in #AgeRelatedDiseases. Thank you, ARDD, for the chance to connect with other experts and learn more about recent advancements in the field.

This #HealthyAgingMonth, Life Biosciences is committed to pioneering therapies focused on treating #AgeReleatedDiseases and extending #healthspan. Learn how we're leveraging the biology of aging to redefine treatment here: https://bit.ly/4dNiwFo